Here are three things to know.
- Hereditary angiodema is a rare, inherited blood disorder where the body does not make enough plasma protein called C1-esterase inhibitor. The disease can cause rapid swelling attacks of the limbs, face, intestinal tract and airway.
- CSL Behring’s drug, Haegarda, is the first self-administered C1 esterase inhibitor injected under the skin to prevent these swelling attacks before they occur.
- Haegarda contains a freeze-dried version of the plasma protein, derived from the plasma of U.S. organ donors.
More articles on supply chain:
Drug manufacturer, distributor shut down for producing unapproved medications
Sanofi CEO on SCOTUS’ biologics ruling: 3 takeaways
Whole Foods acquisition could move Amazon closer to pharmacies
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.